Welcome to our dedicated page for Jasper Therapeutics SEC filings (Ticker: JSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SEC disclosures for an early-stage biotech can feel like a dense immunology textbook. Jasper Therapeutics鈥� filings are no exception鈥攊ts 10-K hides nuanced trial-failure risks, while 8-Ks rush out material updates on JSP191 dose cohorts. Stock Titan offers Jasper Therapeutics SEC filings explained simply, so you can stop combing through pages of FDA terminology.
Our AI reads every Jasper Therapeutics quarterly earnings report 10-Q filing, highlights cash-runway shifts, and translates manufacturing updates into plain English. Curious about Jasper Therapeutics insider trading Form 4 transactions? We stream alerts the instant they hit EDGAR, delivering Jasper Therapeutics Form 4 insider transactions real-time. Need the latest Jasper Therapeutics proxy statement executive compensation? Summaries pinpoint option awards and performance goals. From pipeline milestones to new financing terms, each document arrives minutes after filing鈥攁lready parsed by AI.
Here鈥檚 what you can explore today:
- Jasper Therapeutics annual report 10-K simplified鈥攕ee clinical development risks, R&D spend, and partnership revenue potential.
- Jasper Therapeutics quarterly earnings report 10-Q filing analysis鈥攖rack cash burn against upcoming Phase 1/2 studies.
- Jasper Therapeutics Form 4 insider transactions real-time鈥攎onitor executive stock moves before data readouts.
- Jasper Therapeutics 8-K material events explained鈥攄ecode trial pauses, funding rounds, or leadership changes.
Whether you ask, 鈥淗ow do I read Jasper Therapeutics鈥� 10-K?鈥� or 鈥淲here can I find Jasper Therapeutics executive stock transactions Form 4?,鈥� our platform delivers. Start understanding Jasper Therapeutics SEC documents with AI and make smarter biotech decisions in minutes.
Jasper Therapeutics reported a net loss of $26.7 million for the quarter and $48.0 million for the six months ended June 30, 2025. Cash and cash equivalents were $39.5 million and total assets declined to $46.5 million from $79.9 million at year-end. Research and development spending rose materially to $21.2 million for the quarter (vs. $11.3 million prior year), driving total operating expenses of $27.1 million.
Management concluded substantial doubt exists about the company's ability to continue as a going concern because existing cash is not sufficient to fund operations for at least twelve months. On July 8, 2025 the company implemented a corporate reorganization, reducing headcount by approximately 50% to focus on its briquilimab mast-cell programs, halting enrollment in the asthma study and discontinuing other programs; estimated severance is approximately $1.9 million. Clinical updates show strong preliminary CSU and CIndU responses but an investigation into a drug product lot is underway and may affect select cohorts.
Kingdon Capital Management, L.L.C. and its founder Mark Kingdon have filed a Schedule 13G with the U.S. SEC disclosing a passive ownership position in Jasper Therapeutics, Inc. (NASDAQ: JSPR).
- Shares owned: 765,000 voting common shares.
- Ownership percentage: 5.1% of Jasper鈥檚 outstanding common stock.
- Voting & dispositive power: Both reporting persons hold shared voting and dispositive power over all reported shares; no sole voting or dispositive authority.
- Date of event: 03 July 2025; filing signed 11 July 2025.
- Filing basis: Schedule 13G indicates the stake is for investment purposes only and is not intended to influence control of the issuer.
- Reporting persons: 鈥� Kingdon Capital Management, L.L.C. 鈥� Delaware investment adviser (Type IA). 鈥� Mark Kingdon 鈥� U.S. individual (Type HC, IN). All securities are held on behalf of advisory clients of Kingdon Capital.
- Certification: Both filers certify the shares were 鈥渘ot acquired and are not held for the purpose of changing or influencing control.鈥�
This disclosure places Kingdon Capital among Jasper鈥檚 significant shareholders, crossing the 5% reporting threshold and potentially increasing institutional visibility in the stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.
The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.
Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
